CMCSA CEO Dave Watson said, 'This partnership uniquely brings together more than a decade of technical innovation, national scale, and new opportunities to monetize our combined investment.'įor the fiscal first quarter ended March 31, 2022, CMCSA's revenue increased 13.9% year-over-year to $31.01 billion.

On April 27, 2022, CMCSA and Charter Communications, Inc (CHTR) announced that the two companies had formed a 50/50 joint venture to develop and offer a next-generation streaming platform. The company has three primary businesses: Comcast Cable, NBCUniversal, and Sky. Its Studios segment consists of film and television studio production and distribution operations. Its Media segment consists of television and streaming platforms. Its Cable Communications segment consists of the operations of Comcast Cable, which provides broadband, video, voice, and other services under the XFINITY brand. Click here to see the other ratings of GILD for Growth, Momentum, and Stability.ĬMCSA is a media and technology company. It is ranked #5 out of 401 stocks in the Biotech industry. It has an A grade for Value and a B grade for Sentiment and Quality. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree. It has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. GILD's strong fundamentals are reflected in its POWR Ratings. The stock has lost 13.8% year-to-date to close the last trading session at $62.60. It surpassed Street EPS estimates in three of the trailing four quarters. Also, its non-GAAP EPS came in at $2.12, representing an increase of 3.9% year-over-year.Īnalysts expect GILD's EPS for the quarter ending December 31, 2022, to increase 103.9% year-over-year to $1.41.

The company's non-GAAP income from operations increased 2.9% year-over-year to $3.52 billion. GILD's revenue increased 2.6% year-over-year to $6.59 billion for the first quarter ended March 31, 2022. Kite's CEO Christi Shaw said, 'The FDA approval of our Maryland site marks an important milestone within our global CAR T-cell therapy manufacturing network and will enable us to significantly expand our production capacity and further strengthen our ability to meet the needs of people living with difficult-to-treat blood cancers.' Food and Drug Administration (FDA) had approved commercial production at its new CAR T-cell therapy manufacturing facility in Frederick, Maryland. On April 19, 2022, GILD's company Kite announced that the U.S. Investors can consider adding these stocks to their portfolio based on their strong financials and growth prospects before they blast off. ( GILD ) and Comcast Corporation ( CMCSA ) have faced the brunt of intense selling and are now trading in oversold territory. The economic uncertainties and consequent market corrections have led to many quality stocks entering oversold territory. Having already hiked the interest rates thrice this year, the Fed plans further aggressive interest rate hikes. Investors have been increasingly concerned about a recession this year as the Federal Reserve has been actively trying to control the surging inflation by hiking the benchmark interest rates. The economy has been facing its worst inflation in 41 years, with the June consumer price index rising 9.1% from a year-ago period.

The stock market has experienced a turbulent year so far due to various macroeconomic and geopolitical issues. So, it could be wise to invest in oversold stocks Gilead Sciences (GILD) and Comcast (CMCSA), which have solid rebound potential. The stock market sell-offs triggered by macroeconomic and geopolitical issues since the beginning of the year have driven many quality stocks into the oversold territory.

Buying linkedin stock